Corvus Pharmaceuticals Inc. (CRVS)
NASDAQ:CRVS
Want to see CRVS full AI Analyst Report?
CRVS Stock Chart & Stats
$16.74
-$0.10(-1.74%)
At close: 4:00 PM EST
$16.74
-$0.10(-1.74%)
Day’s Range― - ―
52-Week Range$3.55 - $26.95
Previous CloseN/A
Volume202.27K
Average Volume (3M)1.69M
Market Cap
$1.00B
Enterprise Value$969.82M
Total Cash (Recent Filing)$236.71M
Total Debt (Recent Filing)$834.00K
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 11, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding84,090,420
10 Day Avg. Volume1,242,151
30 Day Avg. Volume1,688,026
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)9.93
Price to Sales (P/S)0.00
P/FCF Ratio-18.44
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-17.63K
Enterprise Value/Ebitda-22.94
Forecast
1Y Price Target
$31.60Price Target Upside88.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Larger Balance-sheet ScaleVery low debt and a marked increase in assets and equity reduce near-term solvency risk and give management structural flexibility to fund R&D and trials. A stronger balance-sheet scale supports partnership or licensing options and extends runway relative to highly leveraged peers.
Positive Phase 1 Soquelitinib Dermatitis DataRandomized Phase 1 results with dose-dependent efficacy, durable remissions, biomarker alignment and a favorable safety profile materially raise the program's probability of success. If replicated in later stages this creates a durable strategic option into the large atopic dermatitis market and potential partnering value.
Expanded ATM And Shelf Registration Boosts Funding OptionalityDoubling at-the-market capacity and having an effective shelf provides structural access to public equity across multiple channels. This funding optionality reduces immediate liquidity pressure, enabling staged clinical development and strategic deal-making without sole reliance on short-term bridge financing.
Bears Say
No Revenue And Widening Net LossesAbsence of operating revenue and substantially larger TTM losses indicate the company remains fully pre-commercial and dependent on capital markets. Widening losses accelerate the need for external financing and increase execution risk if trial outcomes or partner interest do not materialize.
High, Worsening Operating Cash BurnSustained negative operating and free cash flow at this magnitude constrains strategic flexibility and shortens runway absent new capital. Persistent cash burn raises dilution risk, forces pacing of development programs, and could disrupt multi-year trials if raises are untimely or market access tightens.
Loss Of Long‑serving Audit ChairDeparture of a decade-long audit committee chair reduces experienced financial oversight during a critical funding and development phase. The transition risks temporary governance and controls disruption, potentially complicating financing discussions and investor confidence while replacements settle into oversight roles.
Corvus Pharmaceuticals News
CRVS FAQ
What was Corvus Pharmaceuticals Inc.’s price range in the past 12 months?
Corvus Pharmaceuticals Inc. lowest stock price was $3.55 and its highest was $26.95 in the past 12 months.
What is Corvus Pharmaceuticals Inc.’s market cap?
Corvus Pharmaceuticals Inc.’s market cap is $1.00B.
When is Corvus Pharmaceuticals Inc.’s upcoming earnings report date?
Corvus Pharmaceuticals Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 51 days.
How were Corvus Pharmaceuticals Inc.’s earnings last quarter?
Corvus Pharmaceuticals Inc. released its earnings results on May 07, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.008.
Is Corvus Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc.’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc. pay dividends?
Corvus Pharmaceuticals Inc. does not currently pay dividends.
What is Corvus Pharmaceuticals Inc.’s EPS estimate?
Corvus Pharmaceuticals Inc.’s EPS estimate is -0.16.
How many shares outstanding does Corvus Pharmaceuticals Inc. have?
Corvus Pharmaceuticals Inc. has 84,090,420 shares outstanding.
What happened to Corvus Pharmaceuticals Inc.’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went up 6.58%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in CRVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corvus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.60 (88.77% Upside)
$31.60 (88.77% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $333.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
203.05%
12-Months-Change
Fundamentals
Return on Equity
-38.92%
Trailing 12-Months
Asset Growth
325.98%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
CRVS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong positives: robust early efficacy signals (notably cohort 4 AD results), durable responses without rebound, a clean safety profile across >150 patients, supportive biomarker data, favorable PTCL survival metrics versus historical controls, clear plans to expand into multiple indications, and a substantial $189M financing that increases pro forma cash to ~$246M providing runway into Q2 2028. Offsetting factors include materially higher R&D spending, continued quarterly net losses, reliance on small early cohorts pending larger confirmatory trials, timeline uncertainty for registrational data (primary Phase II AD mid-2027; PTCL full readout late 2027), and execution/regulatory risks inherent to multiple concurrent development programs. Overall, the positives (clinical signal, durability, safety, biomarker rationale, and strengthened balance sheet) outweigh the near-term financial and execution challenges, but success depends on upcoming larger trials and interim readouts.View all CRVS earnings summariesCRVS Stock 12 Month Forecast
Average Price Target
$31.60
▲(88.77% Upside)
Technical Analysis
Ownership Overview
22.36% Insiders
11.60% Mutual Funds
45.57% Other Institutional Investors
8.00% Public Companies and
Individual Investors